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Introduction. Carotid artery disease (CAD) comprising high-grade internal carotid artery stenosis (CAS) or carotid artery occlusion
(CAO)may lead to ipsilateral impaired cerebral blood flow and reduced retinal blood supply.Objective. To examine the influence of
chronic CAD on retinal blood flow, retinal morphology, and visual function.Methods. Patients with unilateral CAS ≥ 50% (ECST
criteria) or CAO were grouped according to the grade of the stenosis and to the flow direction of the ophthalmic artery (OA).
Retinal perfusion was measured by transorbital duplex ultrasound, assessing central retinal artery (CRA) blood flow velocities.
In addition, optic nerve and optic nerve sheath diameter were measured. Optical coherence tomography (OCT) was performed
to study retinal morphology. Visual function was assessed using high- and low-contrast visual paradigms. Results. Twenty-seven
patients were enrolled. Eyes with CAS ≥ 80%/CAO and retrograde OA blood flow showed a significant reduction in CRA peak
systolic velocity (no-CAD side: 0.130 ± 0.035m/s, CAS/CAO side: 0.098 ± 0.028; 𝑝 = 0.005; 𝑛 = 12). OCT, optic nerve thicknesses,
and visual functional parameters did not show a significant difference.Conclusion. Despite assessable hemodynamic effects, chronic
high-grade CAD does not lead to gaugeable morphological or functional changes of the retina.
1. Introduction
Carotid artery disease (CAD) comprising high-grade carotid
artery stenosis (CAS) or carotid artery occlusion (CAO) of
the internal carotid artery (ICA) was shown to be associated
with restricted ocular blood flow as measured by Doppler
sonography [1–5]. The higher the grade of CAS, the more
relevant the impairment of the retinal blood flow, especially
if the ophthalmic artery (OA) shows a retrograde blood flow
[6]. A common carotid artery occlusion (CCA-O) impedes
the blood flow of the ipsilateral internal and external carotid
artery (ECA) and is another risk factor for limited orbital
perfusion [7, 8].Ocularmanifestations ofCADare a common
finding, for instance, occurring as amaurosis fugax caused by
acute embolic central retinal artery occlusion or as a chronic
retinal ischemia in the form of ocular ischemic syndrome
(OIS). Retinal examination in CAD patients is generally
performed in direct time relation to the occurrence of clinical
symptoms like sudden or progressive visual loss. However,
it remains unclear whether subclinical retinal abnormalities
or visual impairment occurs. Ultrasound allows reliable
dynamic assessment of orbital blood flow, measured as
central retinal artery (CRA) flow velocity. It can also be used
for structural analysis of optic nerve sheath diameter (ONSD)
and is a proven diagnostic tool to evaluate papilledema in
intracranial pressure with comparable results to MRI exam-
inations [9]. Optical coherence tomography (OCT) allows
reliable quantification of retinal layers and is able to detect
retinal axonal andneuronal loss even in the absence of clinical
visual symptoms inmultiple sclerosis and other CNS diseases
[10–12]. In this pilot study, we analyze the effects of CAD-
induced chronic reduced retinal blood flow on optic nerve
thickness and retinal morphology and function.
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2. Methods
2.1. Patients. Patients were recruited from two hospital ultra-
sound laboratories (Departments ofNeurology: Charite´-Uni-
versita¨tsmedizin Berlin and Ko¨nigin-Elisabeth-Herzberge
Hospital, Berlin) and an outpatient practice in Berlin between
August 2011 and May 2012. After database screening for
chronic high-grade ICA stenosis and ICA occlusion, patients
were selectively invited for an additional study appointment.
Inclusion criteria were unilateral high-grade CAS ≥ 50%
(ECST criteria) [13], CAO or CCA-O, and age > 18. Exclusion
criteria were contralateral CAS ≥ 50% (ECST criteria), con-
tralateral CAO or CCA-O, ICA stent or carotid endarterec-
tomy (CEA), and any ophthalmological diseases potentially
affecting the retina (i.e., glaucoma, advanced diabetes, and
retinopathies). Patients with diabetes were included if they
had not suffered from any ophthalmological symptoms in
their medical history.
2.2. Patient Grouping. The cohort was classified into groups
according to the following hemodynamic criteria:
Group 1: patients with CAS 50% to 79%.
Group 2: patients with CAS ≥ 80% or CAO with a
nonretrograde OA.
Group 3: patients with CAS ≥ 80% or CAO with a
retrograde OA.
Group 4: patients with CCA-O.
A missing blood flow in the OA was defined as nonretro-
grade blood flow.
2.3. Ethics Statement. The study was approved by the Insti-
tutional Review Board (IRB) of the Charite´-Universita¨ts-
medizin Berlin and was conducted in accordance with the
Declaration of Helsinki in its current version and applicable
German laws. All participants gave informedwritten consent.
2.4. Ultrasound. All patients underwent a complete ultra-
sound examination of the extra- and intracranial brain
supplying arteries using a Toshiba PowerVision ultrasound
system (SSA-370A, Toshiba, Japan). Extracranial flow veloci-
tiesweremeasuredwith a linear probe (7.0MHz), intracranial
vessels, and the flow direction of the OA with a sector probe
(1-2MHz). Degree of ICA stenosis was determined according
to the multiparametric DEGUM ultrasound criteria [14].
Transorbital ultrasound was performed with the Siemens
ACUSON (Sequoia 512, Siemens, Germany) and a linear
probe (15.0MHz). The mechanical index (MI) was reduced
(MI < 0.24) according to current standards. As measures of
retinal blood supply, the CRA peak systolic velocity (PSV),
end diastolic velocity (EDV), and the resistive index (RI)
were determined without use of angle correction (see, e.g.,
Figures 1(a)–1(c)). Measurements of the optic nerve sheath
diameter (ONSD) and optic nerve diameter (OND) were
performed according to the method of Helmke and Hansen
[15, 16]. According to the examination conditions, single or
multiple measurements were performed. In case of multiple
measurements, the mean value was used for further analysis.
2.5. Optical Coherence Tomography. Retinal nerve fiber layer
(RNFL) thickness, total macular volume (TMV), combined
ganglion cell and inner plexiform layer (GCIPL) volume, and
optic nerve head volume (ONHV)were obtained from retinal
OCT scans (Heidelberg Spectralis, Heidelberg Engineering,
Germany; Spectralis software version 5.3.3.0; Eye Explorer
Software 1.6.4.0). RNFL thickness was measured with a 12∘
ring scan (3.4mm diameter) around the optic nerve head
using the device’s standard protocol and segmentation algo-
rithm with high resolution mode (1536 A-scans per B-scan)
and activated true track (Figure 1(d)). Whenever possible,
the maximum number of averaging frames in the automatic-
real-time mode (ART) was used. Beside the global RNFL
thickness, the superior, temporal, inferior, and nasal RNFL
quadrant thicknesses were analyzed.
The macular volume was measured using a custom
protocol which generates 61 B-scans focusing the fovea, at a
scanning angle of 30∘ × 25∘ and a resolution of 768 A-scans
per B-scan (ART= 13).TheTMVwas calculated by estimating
the distance between the inner limiting membrane and
Bruch’s membrane in a 6mm diameter cylinder using the
Spectralis software segmentation algorithm.
The GCIPL was segmented from the macular scan with
semiautomatic beta-software provided by the manufacturer
(Eye Explorer Viewing Module Version 5.7). All scans were
checked for algorithm errors and inaccurate segmentation
lines were corrected manually (Figure 1(e)).
TheONHVwas determined from a custom protocol scan
which generates 145 B-scans focusing the optic nerve head
at an angle of 15∘ × 15∘ and a resolution of 384 A-scans per
B-scan (ART = 10). A custom Matlab algorithm was used to
quantify ONHV [17, 18].
All scans were acquired by one experienced operator and
were checked for pathologies and sufficient quality according
to the OSCAR-IB criteria before undergoing quantitative
analysis [19, 20].
2.6. Visual Function. Visual function was testedmonocularly
under best-corrected conditions by one trained examiner
with the Functional Vision Analyzer (Stereo Optical Co.,
Chicago, Illinois) with a simulated distance of 20 ft. High-
contrast visual acuity (HCVA) was tested with Early Treat-
ment Diabetic Retinopathy Study (ETDRS) charts under
photopic conditions (85 cd/m2). Low-contrast visual acuity
(LCVA) was tested with the Functional Acuity Contrast Test
(FACT) under photopic (85 cd/m2) and mesopic (3 cd/m2)
conditionswithout glare [21]. LCVAwas calculated as the area
under the curve (AUC) as previously described [22–24].
3. Results
3.1. Patients. In total, 30 patients could be recruited. Out of
these, 27 had unilateral CAS or a CAO occlusion, while three
patients had a CCA occlusion. Because of the small sample
size, results of the latter group were analyzed separately. A
flow chart of the different patient cohorts in this study is
shown in Supplementary Figure 1 in Supplementary Mate-
rial available online at http://dx.doi.org/10.1155/2015/604028.
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Figure 1: (a)–(c) Transorbital ultrasound measurement of flow velocities in the central retinal artery (CRA) in a patient with carotid artery
occlusion (CAO) and retrograde OA blood flow. (a) Transorbital B-mode scan of the optic nerve and color-mode imaging of the CRA. (b)
Flow velocities ipsilateral to the CAO. Besides the reduced absolute flow velocity, there is a markedly delayed systolic flow rise. (c) Flow
velocity of the no-CAD side. Note the normal steep systolic flow rise. (d) Exemplary peripapillary OCT ring scan with sectors: temporal (T),
superior (S), inferior (I), and nasal (N). (e) Exemplary presentation of an OCT macular volume scan with segmentation of the retinal nerve
fiber layer (RNFL) and combined ganglion cell and inner plexiform layer (GCIPL).
Among the remaining 27 patients with CAD, eight patients
had a CAS between 50 and 79%, seven a CAS ≥ 80% or CAO
with a nonretrograde OA, and 12 a CAS ≥ 80% or CAO with
a retrograde OA. Demographic details of the total cohort and
the stenosis groups are shown in Table 1. All patients were
clinically asymptomatic with no CAD-related symptoms in
the last two months.
3.2. Flow Velocities in the Central Retinal Artery. Three
patients had to be excluded because the CRA was not
detectable on both sides. In the remaining cases, PSV was
significantly reduced on the CAS/CAO side compared to
the no-CAD side in the total cohort (𝑝 = 0.007) and in
Group 3 (CAS ≥ 80%/CAO and retrograde OA, 𝑝 = 0.005)
(see Table 2). Side-to-side comparisons of the individual
measures and intrapatient, intereye differences are shown in
Figure 2. EDV and the RI showed no significant side-to-side
differences in the total cohort or the subgroups (see Table 2).
The level of PSV reduction in the CRA correlates significantly
with the degree of CAS (𝑝 = 0.002, rho = −0.599,𝑁 = 24).
3.3. Subgroup CCA-Occlusion (CCA-O). The three CCA-O
patients showed the following results: PSV CCA-O side:
0.079 ± 0.022m/s, no-CAD side: 0.147 ± 0.046m/s, EDV
CCA-O side: 0.030 ± 0.009m/s, no-CAD side: 0.043 ±
0.015m/s, and RI CCA-O side: 0.62±0.07m/s, no-CAD side:
0.71 ± 0.02m/s. Due to the small group size (𝑁 = 3), no
statistical tests were performed. All three patients had to be
excluded from furthermorphological and functional analysis
(one ocular bulb deformation, one study drop-out, and one
pronounced epiretinal gliosis in a measurement-changing
level).
3.4. Optic Nerve Thickness. There were no significant dif-
ferences of the ON thickness parameters (OND, ONSD) in
the total cohort between the CAS/CAO side and the no-
CAD side. Detailed results of ON thickness measurements
are given in Table 2. Group analyses showed a significant
difference in Group 2 (CAS ≥ 80%/CAO, nonretrograde OA)
between CAS/CAO side and no-CAD side of the OND (𝑝 =
0.027) and the ONSD (𝑝 = 0.028), while there were no
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Table 1: Demographic details of the total cohort and stenosis subgroups. SD: standard deviation; min: minimal; max: maximal; CAD: carotid
artery disease comprising carotid artery stenosis (CAS) and carotid artery occlusion (CAO); HLP: hyperlipoproteinemia; PAD: peripheral
artery disease; TIA: transient ischemic attack; Group 1: CAS 50–79%; Group 2: CAS ≥ 80% or CAO with nonretrograde OA; Group 3: CAS ≥
80% or CAO with retrograde OA.
Total cohort Stenosis subgroups
Group 1 Group 2 Group 3
Patients𝑁 27 8 7 12
Sex
Male 17 (63%) 7 (87.5%) 2 (28.6%) 8 (66.7%)
Female 10 (37%) 1 (12.5%) 5 (71.4%) 4 (33.3%)
Age (years)
Mean ± SD 61 ± 10 66 ± 4 62 ± 7 58 ± 12
(min–max) (35–76) (61–72) (50–71) (35–76)
Disease duration CAD (months)
Mean ± SD 46 ± 50 21 ± 20 74 ± 55 46 ± 56
(min–max) (1–177) (2–58) (6–177) (1–169)
Unilateral CAD
50–79% 8 (29.6%) 8 (100%) 0 0
80–99% 9 (33.3%) 0 5 (71.4%) 4 (33.3%)
Occlusion 10 (37.0%) 0 2 (28.6%) 8 (66.7%)
Comorbidity
Art. hypertension 18 (66.7%) 7 (87.5%) 5 (71.4%) 6 (50.0%)
HLP 14 (51.9%) 4 (50.0%) 3 (42.9%) 7 (58.3%)
Coronary artery disease 8 (29.6%) 4 (50.0%) 1 (14.3%) 3 (25.0%)
Diabetes mellitus 4 (14.8%) 2 (25.0%) 1 (14.3%) 1 (8.3%)
PAD 3 (11.1%) 1 (12.5%) 1 (14.3%) 1 (8.3%)
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Figure 2: Results of peak systolic velocity (PSV) in the central retinal artery (CRA). (a) shows the individual measurements in stenosis
subgroups. (b) shows PSV differences (PSV intereye difference = PSV CAS/CAO side − PSV no-CAD side) of stenosis subgroups. CAD:
carotid artery disease; CAS: carotid artery stenosis; CAO: carotid artery occlusion, Group 1: CAS 50–79%; Group 2: CAS ≥ 80%/CAO with
nonretrograde OA; Group 3: CAS ≥ 80%/CAO with retrograde OA.
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Table 2: Side-to-side differences (no-CAD versus CAS/CAO) of sonographic results in the CRA peak systolic velocity (PSV), end diastolic
velocity (EDV), and resistive index (RI) and the optic nerve thicknesses optic nerve sheath diameter (ONSD) and optic nerve diameter
(OND). Significant findings in PSV for the total cohort (𝑝 = 0.007) and Group 3 (𝑝 = 0.005) and ONSD (𝑝 = 0.028) and OND (0.027) in
Group 2. CAD: carotid artery disease; CAS: carotid stenosis; CAO: carotid artery occlusion, Group 1: CAS 50–79%; Group 2: CAS ≥ 80% or
CAOwith nonretrograde OA; Group 3: CAS ≥ 80% or CAOwith retrograde OA; SD: standard deviation; CoV: coefficient of variation. Paired
sample Wilcoxon sign rank test was used for intereye comparisons (no-CAD versus CAS/CAO).
Total cohort Stenosis groups
Group 1 Group 2 Group 3
PSV
m/s ± SD (CoV)
𝑁 24 6 6 12
No-CAD 0.125 ± 0.030 (0.238) 0.120 ± 0.029 (0.239) 0.119 ± 0.018 (0.152) 0.130 ± 0.035 (0.272)
CAS/CAO 0.105 ± 0.025 (0.241) 0.116 ± 0.023 (0.195) 0.109 ± 0.021 (0.191) 0.098 ± 0.028 (0.287)
𝑝 value 0.007 0.893 0.463 0.005
EDV
m/s ± SD (CoV)
𝑁 24 6 6 12
No-CAD 0.037 ± 0.017 (0.460) 0.034 ± 0.010 (0.308) 0.032 ± 0.009 (0.273) 0.040 ± 0.022 (0.544)
CAS/CAO 0.034 ± 0.014 (0.413) 0.038 ± 0.016 (0.434) 0.033 ± 0.008 (0.225) 0.032 ± 0.016 (0.491)
𝑝 value 0.493 0.463 0.917 0.147
RI
±SD (CoV)
𝑁 24 6 6 12
No-CAD 0.72 ± 0.08 (0.109) 0.71 ± 0.06 (0.089) 0.73 ± 0.04 (0.054) 0.71 ± 0.10 (0.141)
CAS/CAO 0.69 ± 0.10 (0.145) 0.68 ± 0.12 (0.176) 0.70 ± 0.04 (0.052) 0.68 ± 0.12 (0.170)
𝑝 value 0.063 0.416 0.093 0.307
ONSD
cm ± SD (CoV)
𝑁 27 8 7 12
No-CAD 0.477 ± 0.060 (0.125) 0.473 ± 0.066 (0.140) 0.468 ± 0.045 (0.095) 0.484 ± 0.066 (0.113)
CAS/CAO 0.480 ± 0.066 (0.138) 0.465 ± 0.096 (0.207) 0.500 ± 0.047 (0.093) 0.478 ± 0.054 (0.113)
𝑝 value 0.471 1.000 0.028 0.937
OND
cm ± SD (CoV)
𝑁 27 8 7 12
No-CAD 0.291 ± 0.045 (0.156) 0.287 ± 0.059 (0.207) 0.270 ± 0.037 (0.137) 0.306 ± 0.037 (0.119)
CAS/CAO 0.300 ± 0.042 (0.141) 0.295 ± 0.059 (0.199) 0.304 ± 0.027 (0.089) 0.300 ± 0.040 (0.134)
𝑝 value 0.275 0.726 0.027 0.929
significant side-to-side differences in Group 1 (CAS 50–79%)
or Group 3 (CAS ≥ 80%/CAO, retrograde OA).
3.5. Optic Coherence Tomography. Eleven patients had to be
excluded fromOCT analysis due to potentially measurement
influencing pathologies of the retina, among those five
patients with maculopathies, two with local retina atrophies,
and one with macular edema due to traction, or diseases
which could affect the retinal morphology (two patients with
amblyopia, one with optic neuritis in medical history). One
patient did not complete the examinations due to an acute
infection. Exemplary presentation of retinal pathologies with
measurement-changing extent is shown in Supplementary
Figure 2.
Fifteen patients were included into morphological and
functional analysis of the retina. Due to the small sample size,
no subgroup analyses were performed. Instead, correlation
of OCT measures with the degree of CAS and the CRA-
PSV was analyzed to evaluate the relationship between OCT
parameters and the orbital hemodynamic situation. CRA-
PSV was only available for 13 patients because the CRA could
not be detected on both sides in two patients.
Analysis of global and quadrant RNFL thickness, TMV,
GCIPL, and ONHV showed no significant differences
between CAS/CAO side and no-CAD side (Table 3).
Furthermore, no significant correlation with the degree
of CAS or the CRA-PSVwas found (Spearman-Rho test, data
not shown).
3.6. Visual Function. Fifteen patients were included into
functional analysis of the retina. Analysis of HCVA, photopic
LCVA, and mesopic LCVA showed no significant differences
between CAS/CAO side and no-CAD side (Table 3). Further-
more, no significant correlationwith the degree of CAS or the
CRA-PSV was found (Spearman-Rho test, data not shown).
3.7. Correlation between Morphological and Clinical Parame-
ters. All OCT parameters (RNFL thicknesses, TMV, GCIPL,
and ONHV) were tested for correlations with ON thickness
(OND, ONSD), patient age, disease duration of CAS, and
functional visual parameters (HCVA, LCVA). There was a
negative correlation between TMV difference (TMV differ-
ence = TMV CAS/CAO side − TMV no-CAD side) and
disease duration (𝑝 = 0.005). The scatterplot indicates that
there is a cluster of patients with a disease duration of <15
months, which has higher TMV (see Figure 3). All other cor-
relation analyses showed no significant results. Furthermore,
we grouped patients with CAD-associated symptoms (amau-
rosis fugax (AF), transient ischemic attack (TIA), or stroke)
and analyzed OCT parameters. Seven patients of the OCT
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Table 3: Side-to-side differences (no-CAD versus CAS/CAO) of OCT and functional measurements with no significant findings. RNFL:
peripapillary retinal nerve fiber layer; G: global; S: superior; N: nasal; I: inferior; T: temporal; TMV: total macula volume; GCIPL: ganglion
cell/inner plexiform layer; ONHV: optic nerve head volume;HCVA: high-contrast visual acuity; LCVA: low-contrast visual acuity (photopic =
85 cd/m2, mesopic = 3 cd/m2); CAD: carotid artery disease; CAS: carotid artery stenosis; CAO: carotid artery occlusion, ± standard deviation.
Paired sample Wilcoxon sign rank test was used for intereye comparisons (no-CAD versus CAS/CAO).
𝑁 No-CAD CAS/CAO 𝑝 value
RNFL-G thickness (𝜇m) 15 101 ± 8 99 ± 9 0.363
RNFL-S thickness (𝜇m) 15 126 ± 11 126 ± 14 0.363
RNFL-N thickness (𝜇m) 15 76 ± 10 73 ± 14 0.100
RNFL-I thickness (𝜇m) 15 128 ± 15 129 ± 21 0.977
RNFL-T thickness (𝜇m) 15 70 ± 11 69 ± 11 0.637
TMV (mm3) 15 8.62 ± 0.41 8.68 ± 0.41 0.083
GCIPL volume (mm3) 15 1.96 ± 0.12 1.97 ± 0.13 0.344
ONHV (mm3) 13 1.253 ± 0.158 1.275 ± 0.288 0.972
HCVA (decimal) 15 1.11 ± 0.45 1.01 ± 0.31 0.206
LCVA photopic (AUC) 14 1.925 ± 0.198 1.997 ± 0.097 0.158
LCVA mesopic (AUC) 12 1.676 ± 0.333 1.698 ± 0.186 0.937
cohort (𝑁 = 15) had CAD-associated symptoms in their
medical history (2 AF, 1 TIA, and 4 strokes). OCT parameters
on CAS/CAO side with CAD-associated symptoms were
compared with OCT parameters on CAS/CAO side without
CAD-associated symptoms. No significant differences were
found (nonparametric Mann-Whitney 𝑈 test was used).
4. Discussion
This study confirms that chronic high-grade CAS/CAO in
combination with a retrograde OA blood flow leads to
a significant blood flow reduction in the ipsilateral CRA.
Furthermore, our data suggest that these hemodynamic
changes without a clinically manifest pathology do not result
in changes in ON thickness (ONSD and OND), the retinal
morphology (RNFL thickness, TMV, GCIPL volume, and
ONHV), or functionality (HCVA, photopic and mesopic
LCVA).
Kang et al. (2014) showed a subfoveal thinning of the
choroid in three patients with high-grade CAS and OIS by
enhanced depth imaging (EDI) OCT (Heidelberg Spectralis)
[25]. In this study, we did not investigate the choroid
thickness because our images were recorded without EDI
mode. Furthermore, there are currently no reliable automatic
segmentation methods available for the choroid. Instead,
we analyzed state-of-the-art retinal OCT parameters, which
were successfully applied to detect retinal neurodegeneration
in MS and other neurodegenerative diseases, and established
optic nerve ultrasound measures.
The significant side-to-side differences of ONSD (𝑝 =
0.028) and OND (𝑝 = 0.027) in Group 2 (CAS ≥ 80%/CAO,
nonretrograde OA) seem not to be related to the reduced
blood flow in the CRA. If this was the case, there should be a
significant side-to-side difference ofON thicknesses aswell in
Group 3 (CAS ≥ 80%/CAO, retrograde OA), since we found
significant PSV reduction in this group in contrast to PSV in
Group 2 (see Table 2).
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Figure 3: Scatterplot describing the significant correlation (𝑝 =
0.005) between the disease duration of the CAS/CAO and the
intereye difference of the totalmacular volume (TMV). Patients with
initial CAS/CAO diagnosis in the last 15 months show thickening
of the TMV. TMV intereye difference = TMV CAS/CAO side −
TMVno-CADside. CAD: carotid artery disease; CAS: carotid artery
stenosis; CAO: carotid artery occlusion. Spearman-Rho test was
used.
However, patients with initial CAS/CAO diagnosis in the
last 15 months seem to show a thickening of the TMV on the
CAS/CAO side compared to no-CAD side (Figure 3). That
might be explained by an initial retinal edema, an excessive
vascularization, or venous dilatation (overall diameter of
retinal vessels is included in TMV) due to ischemia, which
were regressive during time. Vascular changes and retinal
edema are possible manifestations of an early stage of OIS
[26, 27]. In contrast, RNFL thickness in the nasal quadrant
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tended to show a thinning on CAS/CAO side compared to
no-CAD side; however, this difference was not significant.
This study shows that PSV reduction in the CRA cor-
relates significantly with the degree of CAS (𝑝 = 0.002).
Blood flow velocities in the downstream CRA in CAS ≥ 80%
or CAO are lower if the OA flow is retrograde compared
to those with a nonretrograde OA. To assess whether this
was an effect relevant to the perfusion of the eye, additional
parameters like pulse pressure or ocular perfusion pressure,
assessed by, for example, oculoplethysmography, would have
been desirable but were not assessed in our patient group.
However, data from the literature in fact suggest that PSV
in the CRA significantly correlates with the systolic pressure
in the CRA and OA, supporting our hypothesis of impaired
ocular circulation [3]. Results of the small CCA-O cohort
support the hemodynamic findings and extent of blood
flow reduction, which might occur in such a “worst case
scenario.” In this constellation the ocular blood supply is
severely impaired and collateral compensation can only be
provided via anastomoses from the contralateral external
carotid artery. Unfortunately, our cohort size was small and
the drop-out rate did not allow analyzing retinal structure and
visual function. Patients with such a specific condition tend
to be clinically less stable which might have been the reason
for the low recruitment numbers.
In our study we were not able to perform a full oph-
thalmologic examination including measurement of intraoc-
ular pressure. It is therefore possible that we missed mild
glaucomatous changes that would have not been apparent
in OCT. Spherical refraction was compensated by manually
focusing on the fundus but spherical refraction was not
assessed independently. Consequently we did not employ
exclusion criteria, that is, in regard to high myopia. These
are two clear limitations of our study. However, given the
negative results (also in comparison to normative data in the
device which makes clinical diagnosis of major confounding
conditions improbable), we do not believe that influence on
our results is relevant.Thenegative findings inmorphological
and functional analyses may also be explained with the small
cohort size. To detect small changes, bigger cohort sizes
might be necessary. The decision to choose the intrasubject
comparisons (no-CAD side versus CAS/CAO side) instead of
intersubject comparisons (CAS/CAO eyes versus eyes from
healthy control subjects), which could have gained a larger
cohort size, was made with respect to the comparability
due to the comorbidities. Individual systemic factors have
a greater comparability in intrasubject than in intersubject
comparisons. Still, the lack of a healthy control cohort might
be considered a weakness, because some patients might have
had CAD < 50% on the no-CAD side.
The cohort in this study matches the expected demo-
graphic frame for CAD patients very well and is comparable
to other CAD studies [1–5].
In total, twelve patients had to be excluded from the OCT
analyses,mainly due to retinal pathologies in ameasurement-
changing extent. This finding exemplifies, on the one hand,
that the applicability of quantitativeOCTanalysis is limited in
elderly multimorbid patients. On the other hand, there might
be more appropriate parameters as the ones chosen in this
study. Concerning the brain, CADmore often causes embolic
infarctions while hemodynamic patterns with only 5–8% of
cases are relatively rare [28]. Xu et al. introduced the so-called
RNFL defect, a localized sector in which the RNFL contour
line touched or dipped into the <1% reference zone for a
length of less than 180∘, due to microinfarctions of the retina
of which appearance correlates with arterial hypertension
[29]. Wang et al. found RNFL defects in 48.1% (±4.0 SD,
𝑁 = 154) of patients with acute and in 40.7% (±2.8 SD,𝑁 =
206) of patients with previous stroke [30]. In a retrospective
analysis of our data no such RNFL defects according to
definition of Xu et al. could be found, even though our
cohort includes patients with arterial hypertension (66.7%)
and previous stroke (33.3%). A reason for this finding could
be an improper definition of RNFL defects, our small sample
size, or different ethnic groups (Asian versus Caucasian).
5. Conclusion
High-grade CAS or CAO in combinationwith retrogradeOA
flow leads to a significant blood flow reduction in the CRA
but not to morphological or functional changes of the retina.
Our findings indicate that some patients with a recent CAD
diagnosis can show a significant thickening of the ipsilateral
TMV.We recommend further studieswith a larger cohort size
to evaluate the retinal changes in patients with recent CAD
diagnosis or with acute embolic stroke and to develop and use
adapted OCT parameters for the detection of retinal embolic
defects.
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